We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
-23.1%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$171M
AUM Growth
-$49.1M
Cap. Flow
+$32.3M
Cap. Flow %
18.88%
Top 10 Hldgs %
94.62%
Holding
20
New
4
Increased
–
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
CHMA
Chiasma, Inc. Common Stock
CHMA
+$51.7M
2
CBAY
Cymabay Therapeutics
CBAY
+$4.36M
3
DERM
Dermira, Inc.
DERM
+$1.7M
4
EPRS
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
+$46.4K

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$19.8M
2
ZGNX
Zogenix, Inc.
ZGNX
+$3.92M
3
CEMP
Cempra, Inc.
CEMP
+$1.67M
4
ZLCS
ZALICUS INC COM NEW
ZLCS
+$45K

Sector Composition

Rank Sector Weight
1 Healthcare 86.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CHMA
1
DELISTED
Chiasma, Inc. Common Stock
CHMA
$41.4M 24.16%
+2,080,595
New +$51.7M
TARA icon
2
Protara Therapeutics
TARA
$220M
$27.4M 16.02%
50,447
– –
PRTK
3
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$24.7M 14.43%
1,301,413
– –
SIEN
4
DELISTED
Sientra, Inc.
SIEN
$22.3M 13.04%
219,901
– –
EVAR
5
DELISTED
Lombard Medical, Inc.
EVAR
$12.3M 7.2%
3,473,452
– –
CEMP
6
DELISTED
Cempra, Inc.
CEMP
$10.7M 6.24%
383,935
-45,000
-10% -$1.67M
DRNA
7
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$7.75M 4.53%
945,757
– –
INNL
8
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$6.69M 3.91%
555,555
– –
TBRA
9
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$5.66M 3.3%
589,244
– –
CBAY
10
DELISTED
Cymabay Therapeutics
CBAY
$3.07M 1.79%
+1,600,000
New +$4.36M
ANTH
11
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$2.67M 1.56%
54,749
– –
RGLS
12
DELISTED
Regulus Therapeutics
RGLS
$2.14M 1.25%
2,728
– –
DERM
13
DELISTED
Dermira, Inc.
DERM
$1.62M 0.95%
+70,000
New +$1.7M
ACHV icon
14
Achieve Life Sciences
ACHV
$659M
$1.33M 0.78%
274
– –
CCXI
15
DELISTED
ChemoCentryx, Inc.
CCXI
$1.3M 0.76%
215,000
– –
DCOY
16
Decoy Therapeutics
DCOY
$2.19M
– –
0
– –
EPRS
17
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
$35K 0.02%
+7,896
New +$46.4K
AMRN
18
Amarin Corp
AMRN
$299M
– –
-404,374
Closed -$19.8M
ZGNX
19
DELISTED
Zogenix, Inc.
ZGNX
– –
-36,488
Closed -$3.92M
ZLCS
20
DELISTED
ZALICUS INC COM NEW
ZLCS
– –
-7,896
Closed -$45K

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q3 2015 Portfolio in Review

As of Q3 2015, Abingworth held 20 positions worth $171M, down 22% from $220M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Abingworth deployed $32.3M of net new capital in Q3 2015, opening 4 new positions. Its largest new stake was Chiasma, Inc. Common Stock: 2,080,595 shares worth $41.4M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 86% a quarter earlier.

On the sell side, the largest reduction was Cempra, Inc., an estimated $1.67M trimmed.

  • Abingworth's largest Q3 2015 buy was Chiasma, Inc. Common Stock: 2,080,595 shares worth $41.4M.
  • Abingworth's biggest Q3 2015 reduction was Cempra, Inc., cutting an estimated $1.67M.
  • Abingworth fully exited Amarin Corp in Q3 2015, selling an estimated $19.8M.
  • Abingworth's ten largest holdings make up 95% of its $171M portfolio in Q3 2015.
  • Abingworth opened 4 new positions and closed 3 in Q3 2015.
  • Abingworth's portfolio value fell 22% quarter-over-quarter to $171M.

Based on Abingworth's 13F filing for Q3 2015, filed 13 Nov 2015.